X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA PIRAMAL ENTERPRISES ELDER PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -0.2 10.3 - View Chart
P/BV x 0.1 1.8 5.7% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ELDER PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
PIRAMAL ENTERPRISES
Mar-18
ELDER PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3803,083 12.3%   
Low Rs1881,902 9.9%   
Sales per share (Unadj.) Rs491.2589.7 83.3%  
Earnings per share (Unadj.) Rs-3.2284.0 -1.1%  
Cash flow per share (Unadj.) Rs14.4310.5 4.6%  
Dividends per share (Unadj.) Rs025.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs376.51,467.0 25.7%  
Shares outstanding (eoy) m20.54180.27 11.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.64.2 13.7%   
Avg P/E ratio x-89.38.8 -1,017.2%  
P/CF ratio (eoy) x19.78.0 245.5%  
Price / Book Value ratio x0.81.7 44.4%  
Dividend payout %08.8 0.0%   
Avg Mkt Cap Rs m5,833449,332 1.3%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,17919,881 11.0%   
Avg. sales/employee Rs ThNM15,535.6-  
Avg. wages/employee Rs ThNM2,905.4-  
Avg. net profit/employee Rs ThNM7,482.5-  
INCOME DATA
Net Sales Rs m10,089106,310 9.5%  
Other income Rs m2572,595 9.9%   
Total revenues Rs m10,346108,906 9.5%   
Gross profit Rs m-79251,599 -1.5%  
Depreciation Rs m3614,773 7.6%   
Interest Rs m2,75629,783 9.3%   
Profit before tax Rs m-3,65319,638 -18.6%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125-28,764 -0.4%   
Profit after tax Rs m-6551,203 -0.1%  
Gross profit margin %-7.848.5 -16.2%  
Effective tax rate %-3.4-146.5 2.3%   
Net profit margin %-0.648.2 -1.3%  
BALANCE SHEET DATA
Current assets Rs m9,240118,154 7.8%   
Current liabilities Rs m9,998462,260 2.2%   
Net working cap to sales %-7.5-323.7 2.3%  
Current ratio x0.90.3 361.6%  
Inventory Days Days4627 174.2%  
Debtors Days Days6047 128.8%  
Net fixed assets Rs m10,124113,727 8.9%   
Share capital Rs m206361 57.1%   
"Free" reserves Rs m5,582264,093 2.1%   
Net worth Rs m7,734264,454 2.9%   
Long term debt Rs m4,889242,206 2.0%   
Total assets Rs m22,882726,834 3.1%  
Interest coverage x-0.31.7 -19.6%   
Debt to equity ratio x0.60.9 69.0%  
Sales to assets ratio x0.40.1 301.5%   
Return on assets %11.811.1 105.5%  
Return on equity %-0.819.4 -4.4%  
Return on capital %22.310.3 216.5%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30715,110 2.0%   
Fx outflow Rs m1254,298 2.9%   
Net fx Rs m18110,813 1.7%   
CASH FLOW
From Operations Rs m11,754-159,666 -7.4%  
From Investments Rs m-561-17,677 3.2%  
From Financial Activity Rs m-6,762186,503 -3.6%  
Net Cashflow Rs m4,4329,364 47.3%  

Share Holding

Indian Promoters % 39.6 52.9 74.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 4.0 187.5%  
FIIs % 16.8 26.6 63.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 16.5 218.8%  
Shareholders   16,479 93,274 17.7%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   UNICHEM LAB  VENUS REMEDIES  STERLING BIOTECH  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Losses; Rupee Devalues to Record Low(12:30 pm)

Stock markets in India trim losses to turn flat even as rupee fell 43 paise to hit record low of 70.29 against the US dollar.

Related Views on News

PIRAMAL ENTERPRISES Plunges by 5%; BSE HEALTHCARE Index Up 0.4% (Market Updates)

Aug 16, 2018 | Updated on Aug 16, 2018

PIRAMAL ENTERPRISES share price has plunged by 5% and its current market price is Rs 2,832. The BSE HEALTHCARE is up by 0.4%. The top gainers in the BSE HEALTHCARE Index are ALEMBIC PHARMA (up 5.4%) and SHILPA MEDICARE (up 4.8%). The top losers is PIRAMAL ENTERPRISES (down 5.1%)..

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS